$NWBO

Read!

Best news this week. 👍🏻

$NWBO

UK Parliament Response on DCVax-L (April 28, 2025)

One of Sarah Owens’ questions has been answered.

questions-statements.parliament.uk/written-questi… 1/5

Official UK Parliament answer confirms:

•DCVax-L is not yet licensed by MHRA.

•NWBO has submitted the application and is fully engaged with MHRA.

No rejection, no pause — review ongoing.

$NWBO

1/7

If $NWBO’s DCVax-L is approved for both Grade 3 & 4 gliomas, covering newly diagnosed and recurrent GBM, it’s a major leap forward — not just a drug approval, but platform validation.

Here’s what it would mean: 2/7

Such a broad label would:

• Expand the patient population
• Boost valuation
• Open doors to pan-solid tumor use
• Strengthen NWBO’s case for NICE + EU filings

It flips the “niche drug” narrative on its head.

1/

$NWBO trading has been suspended on Börse Stuttgart since April 9.

No trades. No fix. No public explanation.

While Stuttgart is a secondary exchange, this extended halt may carry broader implications.

Here’s what we know.

Thanks to @smith348572 for due diligence 🙏🏻 2/

Börse Berlin — another German exchange — publicly warns that OTC stocks can be subject to fraudulent trading practices that occur simultaneously in the U.S. and Germany.

This highlights cross-market vulnerabilities, particularly in thinly traded securities.

$NWBO

NICE updated status on NWBO collaboration.

ChatGPT, Grok & Gemini say:

"NICE’s active appraisal of DCVax-L signals MHRA approval is imminent or already granted — unlocking the path to NHS funding, UK rollout, & real revenue.
👉 Huge validation for $NWBO & patients."

👇 ChatGPT:

💥 NWBO milestone:

NICE (UK) is appraising DCVax-L for glioblastoma (GID-TA10143).

This strongly signals MHRA approval is imminent—or already granted (but not yet announced).

It’s about routine NHS use. Here’s why:

$NWBO

$NWBO

Spoofing has continued until the ruling. Probably also naked shorting.

Would market makers be able to continue and hope this will not be revealed during discovery or would they be better of to stop?

$NWBO

I have made several AI's concurrently look into all SEC filings, PR's, ASMs and all criticism today on Investorshub into this thesis, and correlating their answers between them:

Was Flaskworks EDEN
included in the
MAA for DCVax-L?

In short? prnewswire.com/news-releases/…

$NWBO

Thanks to @voloda37814097 for this.

🚨 MY FINAL TAKE on MHRA’s MIA Update (UK MIA 54923) & DCVax-L! 🚨

MHRA shifting Advent’s MIA from “Human” to Regulation 17 (Wholesale Distribution) is a BIG SIGNAL for DCVax-L’s path to commercialization. Let’s break it down 🧵👇 1️⃣ What This Means: A Distribution Step
🔹 MHRA updated Advent’s MIA on Feb 28, 2025 from “Human” to “Regulation 17”
🔹 R 17 covers wholesale authorization → Advent may now distribute DCVax-L
🔹 Ties into MHRA’s ATMP framework & post-approval steps → Getting DCVax-L to patients

$NWBO

🚨 MY TAKE on Advent’s MIA Update
(Feb 27, 2025)! 🚨
MIA 54923 updated again in under a week—Feb 20 GMP, Feb 27 MIA.

What’s up? 🔹 Facility Upgrades Likely – I’m With ChatGPT ✅ – I think this could signal upgrades at Advent’s Sawston site, like enhancing capacity or tech (e.g., Flaskworks EDEN for DCVax-L). MHRA’s Feb 20 GMP (1-day cert) —new equipment or processes might need swift MIA updates.

$NWBO

Is the “New” Murcidencel Trial Actually an Old One? A Closer Look at the Evidence

Recently, a new clinical trial under the name Murcidencel appeared in European clinical trial databases.

🔗 Murcidencel Trial:

(1/🧵)clinicaltrials.eu Strange Detail: The Murcidencel trial has a start date of 2015 - the same period when an earlier dendritic cell vaccine (DC) trial was conducted.

The old trial, published July 2024, did not specify the vaccine’s name.

🔗 Old Trial (July 2024):

(2/🧵)onlinelibrary.wiley.com

$NWBO

Interesting take from flipper



Let's put that to a test through several AI models investorshub.advfn.com/boards/read_ms…

$NWBO

There's a lot of unsubstantiated bullshit to counter this weekend, in order to downplay the potential of fridays R&R.

Once more a simplified take from DennisDave on discovery.



Let's pull its premisr apart bit by bit.

And please do share 🙏🏻investorshub.advfn.com/boards/read_ms…

$NWBO

DennisDave on Ihub continues not to feed ChatGPT, but to starve it from information to be able to make it correlate his bias.

Lets make ChatGPT refute itself, by having provided it with essential information as well as his post here.

investorshub.advfn.com/boards/read_ms…

$NWBO @cvpayne @kshaughnessy2

Fudders are clueless as to how NWBO will be allowed to dig deep during discovery, like the precedents of the Harrington and Phunware lawsuits.

Just focusing on May 10th 2022 can be catastrophic for market makers and @adamfeuerstein

https://twitter.com/fyre02532/status/1885799554668192171

$NWBO

It's not silence from the company, that suppress the share price.

It is plain and simple, manipulation, spoofing and counterfitting.

Guidance and information have zero effect, before AFTER approval.

It HAS been tried, and the forces aligned against NWBO, has used it ... ... against NWBO through complaints, through fraud lawsuits, through misinterpreting the info.

Best case its like pissing your pants in december walking around Nova Scotia.

What a nice feeling and then ...

You don't want to RISK have to divert attention, money and effort ...

$NWBO

If trading of an over-the-counter (OTC) stock like NWBO (Northwest Biotherapeutics) is halted in Europe, it can significantly affect market makers who have engaged in naked short selling of the stock. Here’s how: 1Liquidity Impact: With the trading halt, the liquidity of NWBO in the European market is essentially frozen. Market makers rely on liquidity to cover their short positions, including naked shorts. Without the ability to trade, they cannot buy shares to close out these positions

$NWBO

A case AGAINST reverse split (R/S)

Once again we have the "tool" R/S mentioned, as a mean with which we can uplist to Nasdaq and get institutions to buy in.

I have earlier pleaded my case against it and will continue to do so.

1/12 An R/S is market makers, shorters and fudders wet dream to make it much easier to spoof/naked shart the share price to lower levels.

NO uplist should take place founded in R/S if any of the following has not occured.

2/12

$NWBO

I asked ChatGBT, who is SIO Capital Management?

SIO Capital Management, LLC is a global equity market neutral healthcare hedge fund headquartered in New York. Founded by Dr. Michael Castor in 2006, the firm focuses exclusively on the healthcare sector .... ... which includes areas such as biotech, pharmaceuticals, medical devices, insurance, and hospitals. This specialization allows SIO to leverage its deep industry knowledge to identify investment opportunities and mispriced stocks within the complex healthcare landscape.

$NWBO

If you are STILL unaware, @SECGov and @GaryGensler are NOT a friend of "us".

Citadel and Virtu have built up an enormous liability post on their yearly financial condition statement, named

"Securities sold, not yet purchased at fair value”.

Essentially is is a ...

https://twitter.com/garygensler/status/1633198048103759873

... way for market makers to "cover up" their cumulative short and distort scams and give it a "fair value".

Ranging from 45-65 billion dollars the last couple of years, the number is a placeholder for the destruction of companies, for layoff of employees, for preventing ....

$NWBO

The "dormant" company Revimmune Ltd, has been confirmed today, that "its intended future activities are lawful" What does it mean?